Urticarial Vasculitis Associated with Dabigatran

Authors

  • Elisa Macedo Brás Internal Medicine Service. Unidade Local de Saúde de Trás-os-Montes e Alto Douro. Vila Real. Portugal.
  • Raquel Costeira Internal Medicine Service. Unidade Local de Saúde de Trás-os-Montes e Alto Douro. Vila Real. Portugal.
  • Anusca Paixão Internal Medicine Service. Unidade Local de Saúde de Trás-os-Montes e Alto Douro. Vila Real. Portugal.
  • Nuno Ferreira da Silva Internal Medicine Service. Unidade Local de Saúde de Trás-os-Montes e Alto Douro. Vila Real. Portugal.

DOI:

https://doi.org/10.20344/amp.21921

Keywords:

Dabigatran/adverse effects, Vasculitis/etiology

Downloads

Download data is not yet available.

References

Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143:458-66.

Mohamoud M, Horgan C, Eworuke E, Dee E, Bohn J, Shapira O, et al. Complementary use of U.S. FDA’s adverse event reporting system and sentinela system to characterize direct oral anticoagulants-associated cutaneous small vessel vasculitis. Pharmacotherapy. 2020;40:1099-107.

Vu TT, Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation. J Cutan Med Surg. 2017;21:540-50.

An J, Garje R, Wanat KA, Leone JP. Dabigatran-related leukocytoclastic vasculitis. BMJ Case Rep. 2017:bcr2016217423.

Sander R. Dabigatran versus warfarin in patients with atrial fibrillation. Nurs Older People. 2017;29:11.

In Press

Downloads

Published

2024-10-30

How to Cite

1.
Macedo Brás E, Costeira R, Paixão A, Ferreira da Silva N. Urticarial Vasculitis Associated with Dabigatran. Acta Med Port [Internet]. 2024 Oct. 30 [cited 2024 Nov. 7];. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/21921

Issue

In Press

Section

Letters to the Editor

License

Copyright (c) 2024 Acta Médica Portuguesa

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC